AstraZeneca's controversial castoffs continue with $300M heart-drug sale to Recordati

Fierce Pharma ------- As promised, AstraZeneca is forging ahead with its castoff strategy—and this time, rights to an aged beta blocker are on their way out the door. The British pharma giant announced on Monday that it had agreed to sell off European rights to heart med Seloken and related combo Logimax to Italy’s Recordati in exchange for $300 million in a step commercial chief Mark Mallon said in a statement would allow the company to “concentrate our resources on bringing multiple new medicines to patients.” AZ will hang onto the duo in all other markets, it said. “Recordati’s expertise in cardiovascular disease and established European salesforce will help to expand the commercial potential of the Seloken brands, which are mature medicines for the new AstraZeneca,” Mallon added. The pair netted $110 million in sales on the continent last year. To learn more click on the picture below to read the article.